{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.3","upperLimit":"34.6","value":"25.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"description":"Objective response rate was defined as the percentage of participants with a complete response (CR) or a partial response (PR) according to International Working Group (IWG) criteria. The response was assessed based on clinical and radiological criteria. CR is defined as the disappearance of all evidence of disease. PR is defined as a regression of measurable disease and no new sites. As pre-defined, the primary endpoint analysis for this study was based on the Independent Review Committee (IRC) assessment of response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Belinostat 1000 mg/m\\^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.","id":"OG000","title":"Belinostat"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Dataset included participants who received at least 1 dose of belinostat and had a confirmed peripheral T-cell lymphoma (PTCL) diagnosis.","reportingStatus":"POSTED","timeFrame":"24 months","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}